← All news
Markets
STAT+: Why Gilead can’t stop talking about its ambitions in immunology
Gilead Sciences’ top executives have been emphatically bullish about the biotech’s years-long push to develop drugs for inflammatory and autoimmune diseases.
Covered by 1 outlet
All coverage · 1 article